Mostrar el registro sencillo del ítem

dc.contributor.authorMelidou, Angeliki
dc.contributor.authorBroberg, Eeva
dc.contributor.authorEuropean region influenza surveillance network
dc.contributor.authorPozo Sanchez, Francisco 
dc.contributor.authorCasas Flecha, Inmaculada 
dc.contributor.authorLarrauri, Amparo 
dc.contributor.authorOliva Dominguez, Jesus Angel 
dc.contributor.authorDelgado-Sanz, Concepcion 
dc.date.accessioned2023-02-10T11:58:52Z
dc.date.available2023-02-10T11:58:52Z
dc.date.issued2017-09-05
dc.identifier.citationVaccine. 2017 Sep 5;35(37):4828-4835.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15491
dc.descriptionErratum to "Predominance of influenza A(H3N2) virus genetic subclade 3C.2a1 during an early 2016/17 influenza season in Europe - Contribution of surveillance data from World Health Organization (WHO) European region to the WHO vaccine composition consultation for northern hemisphere 2017/18". Vaccine. 2018 May 3;36(19):2740-2741. doi: 10.1016/j.vaccine.2017.12.039. PMID: 29274700.es_ES
dc.description.abstractDuring the European 2016/17 influenza season, A(H3N2) viruses have predominated and the majority clustered in genetic subclade 3C.2a1. Genetic analyses showed that circulating viruses have undergone considerable genetic diversification of the haemagglutinin gene from the current vaccine virus A/Hong Kong/4801/2014 (clade 3C.2a), but the antigenic data that is limited by the challenges with the antigenic characterisation of currently circulating A(H3N2) viruses, showed no clear evidence of antigenic change. The recommended A(H3N2) vaccine component for the northern hemisphere 2017/18 influenza season remained unchanged. However, early and mid-season vaccine effectiveness (VE) estimates were suggestive of reduced VE against A(H3N2) viruses.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectA(H3N2)es_ES
dc.subjectAmino acid substitutiones_ES
dc.subjectEmergencees_ES
dc.subjectEuropees_ES
dc.subjectInfluenza viruses_ES
dc.subjectSeasones_ES
dc.subjectSurveillancees_ES
dc.subject.meshEurope es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInfluenza A Virus, H3N2 Subtype es_ES
dc.subject.meshInfluenza Vaccines es_ES
dc.subject.meshInfluenza, Humanes_ES
dc.subject.meshLectins es_ES
dc.subject.meshWorld Health Organization es_ES
dc.titlePredominance of influenza A(H3N2) virus genetic subclade 3C.2a1 during an early 2016/17 influenza season in Europe - Contribution of surveillance data from World Health Organization (WHO) European Region to the WHO vaccine composition consultation for northern hemisphere 2017/18es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID28780977es_ES
dc.format.volume35es_ES
dc.format.number37es_ES
dc.format.page4828-4835es_ES
dc.identifier.doi10.1016/j.vaccine.2017.07.057es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1873-2518es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.vaccine.2017.07.057es_ES
dc.identifier.journalVaccinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional